Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity

Neurourology and Urodynamics

Volumn 35, Issue 5, 2016, Pages 595-600

  Chartier Kastler, Emmanuel ^a   Rovner, Eric ^b   Hepp, Zsolt ^c   Khalaf, Kristin ^c,d   Ni, Quanhong ^c   Chancellor, Michael ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c ALLERGAN INC   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e BEAUMONT HOSPITAL   (United States)

Author keywords

botulinum toxin A; multiple sclerosis; spinal cord injury; urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; BLADDER CATHETERIZATION; CONTROLLED STUDY; DISEASE ASSESSMENT; EMOTION; FEMALE; HUMAN; INTERMITTENT CATHETERIZATION; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NEUROGENIC DETRUSOR OVERACTIVITY; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; SLEEP; SPINAL CORD INJURY; TREATMENT RESPONSE; URINE INCONTINENCE;

EID: 84973304667     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22757     Document Type: Article

References (25)

1. Hollingworth W, Campbell JD, Kowalski J, et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Qual Life Res 2010; 19:323–31.
2. Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol 2000; 13:263–70.
3. Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil 2001; 80:916–22.
4. Westgren N, Levi R. Quality of life and traumatic spinal cord injury. Arch Phys Med Rehabil 1998; 79:1433–9.
5. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012; 187:2131–9.
6. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. Eur Urol 2011; 60:742–50.
7. Rovner E, Dmochowski R, Chapple C, et al. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2013; 32:1109–15.
8. Ginsberg D, Cruz F, Herschorn S, et al. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 2013; 30:819–33.
9. Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology 2013; 81:841–8.
10. Sussman D, Patel V, Del Popolo G, et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn 2013; 32:242–9.
11. BOTOX. Irvine, CA: Allergan, Inc; 2014.
12. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: A review of the evidence. Biologics 2014; 8:227–41.
13. Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). www.fda.gov 2013 [cited 2014 November 26]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm.
14. Lee KS, Lee YS, Kim JC, et al. Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms. Int J Clin Pract 2012; 66:663–70.
15. Cartwright R, Srikrishna S, Cardozo L, et al. Validity and reliability of patient selected goals as an outcome measure in overactive bladder. Int Urogynecol J 2011; 22:841–7.
16. Choo MS, Doo CK, Lee KS. Satisfaction with tolterodine: Assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract 2008; 62:191–6.
17. Cartwright R, Srikrishna S, Cardozo L, et al. Patient-selected goals in overactive bladder: A placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. BJU Int 2011; 107:70–6.
18. Lowenstein L, FitzGerald MP, Kenton K, et al. Patient-selected goals: The fourth dimension in assessment of pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunt 2008; 19:81–4.
19. Khalaf KM, Coyne KS, Globe DR, et al. Lower urinary tract symptom prevalence and management among patients with multiple sclerosis. Int J MS Care 2015; 17:14–25.
20. Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol 2011; 185:1344–9.
21. Khalaf KM, Coyne KS, Globe DR, et al. The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis. Neurourol Urodyn 2014 [Epub Oct 18] doi: 10.1002/nau.22670
22. Kessler TM, Khan S, Panicker J, et al. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: Short-term effect on quality of life. Obstet Gynecol 2009; 113:1046–51.
23. Brubaker L, Gousse A, Sand P, et al. Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J 2012; 23:1017–25.
24. Payne C, Allee T. Goal achievement provides new insights into interstitial cystitis/painful bladder syndrome symptoms and outcomes. Neurourol Urodyn 2009; 28:13–17.
25. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180:217–22.